Introduction: Tuberculosis is a leading cause of world -wide mortality and morbidity. A reduced rate of tuberculosis in people aged less than 15 years has been seen in Portugal over the last decade of the twentieth century.
Material And Methods: Retrospective analysis of tuberculosis cases in children admitted to the Centro Hospitalar de Vila Nova de Gaia January 1 2000 to December 31 2007. The individual epidemiological, clinical, radiological, microbiological and treatment information was analysed.
Results: We found 23 cases of tuberculosis disease (78% pulmonary tuberculosis and 22% extra- -pulmonary tuberculosis). Children's ages varied from 6 months to 16 years, with the male gender predominant. All patients had previously been vaccinated with BCG and there was a prior contact with TB in 57%. 2007 was the year with the highest number of cases. The Mantoux test was positive in 91% cases and M. tuberculosis isolation was possible in 61%. Gastric fluid analysis allowed isolation in 1/3 of cases and bronchoscopy contributed to M. tuberculosis isolation in 43% cases with negative gastric fluid analysis. Every patient underwent at least 6 months of tuberculostatic treatment, without any documented resistances.
Conclusion: Tuberculosis remains a real problem, with the diagnosis, the search for contacts and adequate treatment (including prophylaxis) the main challenge.
Download full-text PDF |
Source |
---|
Cancer Commun (Lond)
January 2025
Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.
ACS Infect Dis
January 2025
Department of Microbiology and Cell Biology, Indian Institute of Science, C.V. Raman Avenue, Bangalore 560012, India.
Tuberculosis (TB) continues to be a major cause of death worldwide despite having an effective combinatorial therapeutic regimen and vaccine. Being one of the most successful human pathogens, retains the ability to adapt to diverse intracellular and extracellular environments encountered by it during infection, persistence, and transmission. Designing and developing new therapeutic strategies to counter the emergence of multidrug-resistant and extensively drug-resistant TB remains a major task.
View Article and Find Full Text PDFJ Coll Physicians Surg Pak
January 2025
Orthopaedics Department, Gansu Provincial Hospital, Gansu, China.
Null.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Health Informatics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, 196, Gondar, Ethiopia.
Background: To ensure fair access to TB screening, early diagnosis of TB infections, and timely starting of appropriate treatment, mobile technology tools provide convenience and feasibility for communities with limited infrastructure. This study aimed to assess the intention to use mobile-based TB screening among HIV patients in Debre Tabor Town Public health facilities, in Ethiopia.
Method: A facility-based cross-sectional study was conducted among 423 HIV patients.
BMC Microbiol
January 2025
Mycobacteriology Research Center, Institute of Health, Jimma University, Jimma, Oromia, Ethiopia.
Background: Early and accurate diagnosis of drug resistance, including resistance to second-line anti-tuberculosis (TB) drugs, is crucial for the effective control and management of pre-extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB). The Xpert MTB/XDR assay is the WHO recommended method for detecting resistance to isoniazid and second-line anti-TB drugs when rifampicin resistance is detected. Currently, the Xpert MTB/XDR assay is not yet implemented in Ethiopia, thus the MTBDRsl assay continues to be used.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!